# Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx

> **NCT04935177** · PHASE3 · COMPLETED · sponsor: **Hansa Biopharma AB** · enrollment: 64 (actual)

## Conditions studied

- Kidney Transplantation in Highly Sensitized Patients

## Interventions

- **DRUG:** Imlifidase
- **PROCEDURE:** PLEX
- **DRUG:** IVIg
- **DRUG:** Anti-CD20 antibodies
- **DRUG:** Eculizumab
- **OTHER:** Remain on wait list

## Key facts

- **NCT ID:** NCT04935177
- **Lead sponsor:** Hansa Biopharma AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-14
- **Primary completion:** 2025-06-20
- **Final completion:** 2025-06-20
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04935177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04935177, "Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04935177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*